Optimized Treatment of Pulmonary Edema or Congestion

Recruiting Phase 4 Interventional Study
Pulmonary Edema Congestive Heart Failure Acute Heart Failure
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 4
Study type
Interventional
Purpose
Treatment
Participants needed
1,104 (estimated)
Sponsor
Rigshospitalet, Denmark · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Background: Intravenous (IV) loop-diuretics have been a key component in treating pulmonary edema since the nineteen sixties and has a Class 1 recommendation in the 2021 European Society of Cardiology guidelines for heart failure. Conversely, vasodilation was downgraded in the treatment of acute heart failure due to a lack of trials that compare vasodilation with loop-diuretics in a hyperacute cl…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion criteria 1. Age ≥ 18 years 2. Acute (within minutes to days) onset or worsening of subjective dyspnea\* 3. Systolic blood pressure ≥100 mmHg 4. Oxygen saturation \<94% or need of oxygen 5. Signs or suspicion of congestion (peripheral edema, rales, and/or clinical suspicion of congestion) …
Contacts

Johannes Grand, MD, Phd, MPH

+4535452121

johannes.grand@regionh.dk

CONTACT

Jens Jakob Thune, MD, PhD

jens.jakob.thune@regionh.dk

CONTACT